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Abstract: More than half of all pregnant women take prescription medications, raising con-
cerns about fetal safety. Medical databases routinely collecting data from large populations 
are potentially valuable resources for cohort studies addressing teratogenicity of drugs. These 
include electronic medical records, administrative databases, population health registries, and 
teratogenicity information services. Medical databases allow estimation of prevalences of birth 
defects with enhanced precision, but systematic error remains a potentially serious problem. In 
this review, we first provide a brief description of types of North American and European medical 
databases suitable for studying teratogenicity of drugs and then discuss manifestation of system-
atic errors in teratogenicity studies based on such databases. Selection bias stems primarily from 
the inability to ascertain all reproductive outcomes. Information bias (misclassification) may be 
caused by paucity of recorded clinical details or incomplete documentation of medication use. 
Confounding, particularly confounding by indication, can rarely be ruled out. Bias that either 
masks teratogenicity or creates false appearance thereof, may have adverse consequences for 
the health of the child and the mother. Biases should be quantified and their potential impact on 
the study results should be assessed. Both theory and software are available for such estimation. 
Provided that methodological problems are understood and effectively handled, computerized 
medical databases are a valuable source of data for studies of teratogenicity of drugs.
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Introduction
In Western countries, more than half of pregnant women take prescription medication, 
and nearly all pregnant women use over-the-counter medications, vitamins or other 
dietary supplements.1–4 Drugs that are safe for adults may be teratogenic for the devel-
oping fetus. The majority of drugs or their metabolites cross the placental barrier,5 and 
metabolites may be more fetotoxic than their source substances, as was noted in the 
case of thalidomide-induced phocomelias.6 Because pregnant women rarely participate 
in randomized studies of medicines, evidence from observational studies is central in 
establishing safety of prenatal drug exposure.7
Since birth defects are rare, assembling cohorts to observe their occurrence is 
expensive in terms of time, money, and resources, leading to widespread use of the 
case-control design. Case-control studies, often based on interviews or questionnaires, 
are susceptible to selection and recall bias, and they do not allow estimation of abso-
lute risks (prevalences) of birth defects. Existing medical databases are increasingly 
being used to conduct pharmacoepidemiologic cohort studies, including studies 
of drug teratogenicity.8 Medical databases, some of which have been in existence Clinical Epidemiology 2010:2 38
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for decades,9,10 prospectively and routinely record health 
data, enabling relatively quick and inexpensive analyses of 
data from large populations.8 Such analyses allow direct 
estimation of birth defects’ prevalences, while estimates of 
association are less susceptible to selection or recall bias 
obtained in studies with primary data collection.11 Medical 
databases have their own limitations, however, which must 
be considered when interpreting findings of studies based 
on their data.8
In this paper, we first provide examples of established 
North American and European medical databases suitable 
for studying teratogenicity of drugs, and then describe com-
mon epidemiologic biases as manifested in studies based on 
such databases.
Medical databases for studying 
teratogenicity of drugs
Medical databases are data repositories that contain heath-
related data, including electronic medical records, admin-
istrative databases such as claims records, and registries of 
diseases and rendered health services.8,12 Medical databases 
are typically maintained for surveillance or reimbursement, 
meaning that the influx of data into them is decoupled 
from research purposes. Therefore linkage of records from 
different databases covering the same population may be 
required in order to combine in the same dataset information 
on prenatal drug exposure, occurrence of birth defects, and 
relevant covariates. Independence of data collection from 
research hypotheses reduces risk of self-selection bias, but 
limits the variables available for analysis to those routinely 
collected by the databases.
In the United States, Medicaid, a health care plan for low-
income persons, maintains claims databases of its enrollees. 
Low-income pregnant women, and children under the age of 
6 years, are eligible for Medicaid coverage, which includes 
access to prescribed drugs.16 Each state administers its own 
Medicaid program, and patient eligibility and available 
services vary from state to state.17
Private insurers in the US also maintain claims databases 
that compile data on maternal use of prescribed drugs and 
on birth defects as a part of an overall diagnostic record. 
For example, the health management organization (HMO) 
Research Network combines data maintained by several 
managed-care health plans (such as Kaiser Permanente or 
Harvard Pilgrim Health Care).18 The network is part of the 
national initiative under the aegis of the Department of Health 
and Human Services “to increase awareness of the benefits 
and risks of therapeutics”.18 Each participating health plan 
maintains computerized databases of member enrollment, 
filled prescriptions, and diagnoses made during outpatient 
visits and hospitalizations.18
In Canada, the Saskatchewan Health Services Databases 
cover 99% of the population of the Saskatchewan province 
(about 1 million persons or 3.2% of the Canadian population). 
Residents of the province have universal health coverage, 
including prescription medication reimbursement. Drug 
teratogenicity may be studied by linkage of databases on 
vital statistics (live and still births), outpatient prescriptions, 
and hospitalization services. The linked data are available for 
research use, provided they remain unidentifiable to ensure 
data protection.19
The United Kingdom’s Medicines and Healthcare prod-
ucts Regulatory Agency (MHRA) hosts the General Practice 
Research Database (GPRD), which is one of the largest and 
the most complete databases, containing medical records on 
more than 4 million patients, including prescribed medica-
tions, referrals and diagnoses made during hospitalizations 
and visits to general practitioners (GPs).13–15 The database 
was established in 1987, and its data are linkable to the UK’s 
other medical databases.13
In the course of the past two decades, all Nordic coun-
tries (Denmark, Finland, Iceland Norway, and Sweden) have 
established prescription databases,21–23 tracking prescription 
medications dispensed in outpatient pharmacies. The earli-
est database (in Denmark) was established in 1989, while 
the newest (in Sweden) was launched in 2005 (for a recent 
review of Nordic prescription databases, see review by Furu 
and colleagues21). In Sweden, maternal use of medication 
in pregnancy is also available, since 1995, as measured by 
self-reporting during the first antenatal visit.24
Drawbacks of North American databases maintained by 
health insurers or based on residence include nonuniform 
eligibility; selective coverage (eg, the poor or the employed); 
and potential loss to follow-up if patients cease to be eligible 
for coverage after changes in income, employment, or resi-
dence. By contrast, medical databases in Nordic countries 
are derivatives of universal and uniform health coverage of 
welfare states.20 Thus, in contrast to the North American 
databases, membership in a Nordic medical database is 
independent of income, employment, or residence.21
Sources of data on birth defects and other reproductive 
outcomes in Nordic countries include birth registries,9,24,25 
hospital discharge registries,26 and registries of congenital 
malformations.24,26,27 Birth registries, with records dating 
back to the 1960s or 1970s,9,25 typically record birth defects 
discovered immediately after birth, and therefore must be Clinical Epidemiology 2010:2 39
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supplemented with data from hospital registries and regis-
tries of congenital malformations.24,27,28 Hospital registries, 
congenital malformation registries, or induced abortion reg-
istries26 can also be used to ascertain reproductive outcomes 
other than live or still births. Miscarriages, and elective or 
therapeutic pregnancy terminations, including those done 
after prenatal diagnosis, and some data on malformations 
also may be available.26,28 Data from medical databases can 
be linked to other registries containing demographic, social, 
and labor-market data. This is especially true for Denmark, 
whose network of population databases has been described 
as “the most complete and interwoven collection of statistics 
touching on almost every aspect of life”.10,26
A crucial advantage of Nordic databases is the possibility 
of across-the-board data linkage via unique identification 
number, assigned at birth and encoding date of birth and sex, 
which follows each citizen “from cradle to grave”.10,21,29 Birth 
registry records contain the maternal identification number, 
which is a necessary link for unambiguous ascertainment 
from prescription databases of maternal drug intake during 
pregnancy.26
Teratology information services (TIS) counsel newly 
pregnant women, or women who are trying to conceive, 
regarding safety of medication use. The European Network 
of Teratology Information Services lists about 25 European 
and South American TIS,30 and a similar number is listed 
by the US-based Organization of Teratology Information 
Specialists of the United States and Canada.31 TIS record 
the women’s demographic, obstetrical, medical, and drug-
exposure history.31 During the year after the expected delivery, 
the TIS conducts a follow-up interview, collecting data on 
malformations. Reporting to TIS is initiated by women and 
is thus not systematic. Therefore, despite availability of large 
numbers of computerized records, TIS-based studies on tera-
togenicity of drugs are similar to epidemiologic studies with 
primary data collection in their susceptibility to self-referral 
bias, and nonrandom losses to follow-up. Furthermore, TIS 
may cover diverse geographic areas, making it difficult to 
establish a reference for an expected number of malformations 
in the source population.
Medical databases (summarized in Table 1) are widely 
used for addressing teratogenicity of drugs. Examples 
include use of the GPRD study on anticonvulsants;32 the 
Tennessee Medicaid study on angiotensin-converting 
enzyme inhibitors,33 a TIS-based study of prenatal lorata-
dine exposure;34 studies of antidepressants from US claims 
databases,35 the Saskatchewan Healthcare Databases,36 
the population databases of Sweden,37 Denmark,38 and on 
TIS.39
Bias in studies of medical databases
Large sample sizes, obtainable from medical databases, 
may reduce random error around the resulting estimates, 
but systematic error remains a problem.40 All three main types 
Table 1 Examples of North American and European medical databases suited for studies of teratogenicity of drugs
Example of a database or a 
linked set of databases
Country Population covered Measure of prenatal  
drug exposure
Measure of birth defects’  
occurrence
Medicaid16 USA Pregnant women and children  
eligible as determined by  
state-specific low-income  
definitions
Medicaid maternal  
pharmacy files
Medicaid-maintained  
records of hospitalizations,  
emergency-department and  
outpatient physician visits
Private insurance claims  
databases18
USA Enrollees of participating  
health care plans, such  
as HMOs
Health-plan maintained  
records of dispensed  
prescriptions
Health-plan maintained  
hospitalization, outpatient, and  
emergency-department records
Saskatchewan Health  
Services Databases19
Canada Population of the  
Saskatchewan  
province (99%)
Outpatient prescription  
drugs database
Hospitalization database  
Medical services database  
vital statistics database
The General Practice  
research Database13–15
UK A sample of UK patients Electronic medical  
records
Electronic medical records
Population medical  
Databases of Nordic  
countries9,21–25
Denmark, Finland,  
iceland, Norway,  
Sweden
Entire country  
populations
Nationwide and regional  
prescription databases;  
maternal self-report  
recorded in the birth  
registry
Birth registries, registers of  
congenital malformations,  
hospital discharge registries,  
registries of induced abortions
Teratology information  
services30,31
worldwide May or may not cover a  
well-defined population
Self-report by women Self-report by women during  
a TiS-conducted interviewClinical Epidemiology 2010:2 40
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of epidemiologic bias – selection bias, information bias, and 
confounding – occur in studies of medical databases.
Selection bias
In an ideal cohort study of drug teratogenicity, an investigator 
would recruit cohorts of women exposed and unexposed to 
a given agent before conception and examine birth defects 
detected among the fetuses throughout gestation, at birth, 
and several years postnatally. In such an ideal setting, the 
incidence rate of a birth defect is the number of all fetuses 
or neonates with that defect, detected at any time during the 
follow-up, divided by the total person-time contributed by 
all fetuses at risk. In reality, neither reproductive outcomes 
nor total person-time contributed by the initial conceptuses 
is fully observable (respectively, the numerator and the 
denominator of the incidence rate).
Two major sources of selection bias are relevant to the 
study of drug teratogenicity: spontaneous fetal loss (extra-
uterine pregnancy, miscarriage, stillbirth), and induced 
abortion. Malformations associated with first-trimester mis-
carriages are not always recorded or observable (Table 2).28 
Elective pregnancy terminations during the first trimester 
are usually unrelated to medication use or suspected birth 
defects.41,42 Second-trimester induced abortions are com-
monly carried out after diagnosis of malformation by pre-
natal diagnosis. The proportion of malformations diagnosed 
prenatally varies geographically (eg, 25% in Croatia vs 88% 
in Paris)43 and according to local availability of relevant pro-
cedures.44 Furthermore, rates of second-trimester pregnancy 
terminations depend on local laws, severity of birth defect, 
and long-term prognosis.43 Up to 94% of fetuses with pre-
natally diagnosed fatal malformations (eg, anencephaly) are 
aborted, compared with 30% to 40% of fetuses with treatable 
malformations (eg, diaphragmatic hernia or transposition of 
great arteries).43 In Sweden, 60% of spina bifida cases were 
diagnosed at elective termination of pregnancy between 18 
and 22 weeks’ gestation, and the level of ascertainment of 
spina bifida was inversely related to achieved gestational 
age at pregnancy end (birth or pregnancy termination).28 In 
contrast, diagnosis of cleft palate rarely led to pregnancy 
termination.28 In the US, between the 1970s and the 1990s, 
use of ultrasonography or amniocentesis for prenatal diag-
nosis has increased from 7% to nearly 90%, while the rate 
of elective abortions for any malformation increased from 
0.8% to 18%, with a larger absolute increase among termi-
nations for nonfatal malformations.45 Finally, access to and 
utilization of prenatal diagnosis may depend on a pregnant 
woman’s socioeconomic status, race/ethnicity, or age.46 Thus, 
severity of selection bias resulting from second-trimester 
pregnancy terminations may vary according to geography, 
type of malformation, timing of termination, calendar time, 
and maternal characteristics.
In summary, in cohort studies of birth defects, inability 
to observe birth defects at all reproductive outcomes repre-
sents loss to follow-up of a potentially nonrandom subgroup 
of embryos and fetuses. Selection bias ensues if either the 
medication or the malformation affects an embryo’s survival 
until malformation can be observed. Such bias can cause a 
spurious apparent association between drug exposure and 
medicinal agent or, alternatively, lead to erroneous conclu-
sions about the lack of an association.47 To reduce selec-
tion bias, whenever possible, all observable reproductive 
outcomes should be ascertained as well as malformations 
detected both prenatally and at birth.48
information bias
In database studies of drug teratogenicity, relying on dispensed 
prescription information to ascertain drug use in pregnancy 
may lead the investigator to erroneous assumptions regarding 
the fact, the timing, and the dosage of medication intake.49 
Such misclassification is an important limitation given the 
short duration of gestation and even shorter duration of 
developmental “critical periods”, during which birth defects 
can plausibly occur as a result of drug exposure. A major 
Table 2 Outcomes of gestation and detection of birth defects
Gestational 
period
Trimester I  
(up to week 12)
Trimester II  
(13–28 weeks)
Trimester III  
(28 weeks)
reproductive  
outcomes
Early spontaneous pregnancy loss due to chromosomal  
abnormalities (eg, most trisomies)  
Early miscarriage, malformation rarely observed  
Nontherapeutic elective abortion
induced pregnancy termination  
after prenatal diagnosis  
Late spontaneous miscarriage
Live birth  
Still birth
Detection of  
malformations
Spontaneous abortions of chromosomal abnormalities and  
elective abortions are unlikely to be related to malformation  
or drug use  
Other birth defects are not observable
Birth defects are observable  
to some extent
Birth defects are  
observableClinical Epidemiology 2010:2 41
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drawback of prescription registries is lack of data on adherence 
once medication is dispensed. Adherence may be indirectly 
measured by the number of filled prescriptions. Furthermore, 
medication dispensed during hospitalization or in outpatient 
clinics are not recorded in prescription registries potentially 
leading to under-ascertainment of medication use.21 Nondif-
ferential misclassification of maternal drug exposure, if severe, 
may nullify the observed estimate of effect, if an effect exists. 
The direction of bias resulting from differential misclassifica-
tion of maternal medication use is unpredictable.
Presence of a birth defect is also subject to misclassifica-
tion. The proportion of true cases of birth defects captured 
by electronic sources (completeness, analogous to sensi-
tivity)50 may vary widely by type of anomaly and type of 
data source.51,52 In the Saskatchewan Health Databases, for 
example, data in the hospitalization records may be suitable 
for studying only major birth defects.19 Imperfect sensitiv-
ity of birth defect measure leads to underestimation of true 
prevalence of birth defects, but imperfect sensitivity alone 
does not bias a relative estimate of effect. If no other bias 
is at work, relative estimate of effect will be unbiased53 in 
the absence of false-positive records of birth defects (100% 
specificity), which is usually the case for electronic records 
of birth defects.54
In summary, data on medication use and occurrence of 
birth defects in medical databases are of varying quality, 
depending on method of data collection and on the type 
of medication and birth defect under study. A researcher 
embarking on a study of teratogenicity should obtain infor-
mation about validity of data on the variables of interest in 
a selected data source.
Confounding
Predictors of medication use by a pregnant woman that are 
independent risk factors for a given birth defect can confound 
the estimate of association between the medication and the birth 
defect under study. Examples of potential confounding factors 
include geography, maternal age, race, socioeconomic status, 
and the disease for which the medication is prescribed.55
Unmeasured or unknown confounding cannot be con-
trolled in an analysis, except indirectly, if unmeasured traits 
happen to correlate with measured and controlled characteris-
tics. Residual confounding, which can be viewed as a special 
case of unmeasured confounding, occurs when controlling 
for a variable used to measure a confounding factor does 
not completely remove confounding by that factor. This 
may occur when the variable is misclassified owing to poor 
measurement or inadequate categorization. The estimate of 
effect adjusted for a misclassified version of a confounder is 
biased in the direction of confounding. If adjusting for a mis-
classified confounder variable attenuates the crude estimate, 
adjustment for a perfectly measured confounder is expected 
to result in further attenuation, while amplification of effect 
estimate by a misclassified confounder variable indicates that 
the true effect may be larger than the apparent one.
Confounding by indication is common in studies of 
unintended effects of drugs, because of the difficulty in 
separating the effect of a given drug from the effect of the 
disease for which the drug is given (the indication). Thus, 
a maternal diseases itself – rather than medication used to 
treat it – may increase risk of malformation in offspring. To 
counter confounding by indication, one may examine risks 
of birth defects among offspring of mothers taking the same 
medication prescribed for different indications and among 
offspring of women with similar indications taking different 
drugs. These methods may only partially address confound-
ing by indication since use of different medications for the 
same indication may vary according to severity or etiology 
of disease, both of which may affect fetal risks. One way to 
address confounding by indication is by taking advantage of 
the time-sensitive nature of the relation between drug expo-
sure and the possible birth defect. For example, causation 
between cardiac malformations and drug exposure cannot be 
inferred if the drug exposure occurred only during second and 
third trimester, ie, after the heart had been formed.12
Selection bias, information bias, and confounding are all 
at work simultaneously in a given epidemiologic study, and 
may bias estimates in the opposing directions. It is therefore 
difficult to know the magnitude and direction of the net bias. 
Theory and software have been developed to quantify the 
impact of study estimates by unmeasured confounding,41,56 
and misclassification of study variables.57–62 The methods are 
based on subjecting study results to an “array of informed 
assumptions”62 about the source and the magnitude of sys-
tematic error. Many available methods tend to apply to simple 
situations, such as those characterized by dichotomous study 
variables. However, even rough quantification of bias is an 
improvement over sometimes insufficiently justified asser-
tions and beliefs regarding its direction and impact.57
Conclusion
With respect to teratogenicity of drugs, any effect – harmful, 
neutral, or protective – has important implications for preg-
nant women and their offspring. Bias masking a true terato-
genic drug effect would result in continued use of a harmful 
agent, while bias creating false appearance of teratogenicity Clinical Epidemiology 2010:2 42
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may limit treatment options available to pregnant women. 
These could include treatments for chronic conditions that 
may themselves detrimentally affect pregnancy outcome if 
left untreated.
Provided that methodological problems are understood 
and effectively handled, computerized health care databases 
are a valuable source of data for cohort studies of teratoge-
nicity of drugs.
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